Differential blood count as triage tool in evaluation of pelvic masses
ObjectiveTriaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables a...
Saved in:
| Published in | International journal of gynecological cancer Vol. 31; no. 5; pp. 733 - 743 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.05.2021
by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1048-891X 1525-1438 1525-1438 |
| DOI | 10.1136/ijgc-2019-001103 |
Cover
| Abstract | ObjectiveTriaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables and preoperative differential blood counts to improve detection of ovarian cancer over CA125 alone.MethodsFrom pathology reports, patients were classified as having: epithelial ovarian cancer (n=743), including fallopian tube and primary peritoneal cancer, non-epithelial ovarian cancers (n=46), non-ovarian cancers (n=122), or benign disease (1,129). From women with epithelial ovarian cancer, we excluded those who received prior neoadjuvant chemotherapy (n=19). Women were also excluded if they did not have a serum CA125 or complete blood count measured within 180 days prior to surgery (n=1099) or did not have both tests within 90 days of each other (n=13). Categorizing patients by menopausal status, we calculated Pearson correlations between differential counts or ratios and CA125, and used t tests to identity univariate predictors of malignancy and stepwise logistic regression and likelihood ratio tests to create models best distinguishing epithelial ovarian cancer from benign disease.Results337 women with epithelial ovarian cancer and 365 with benign disease were included in the analysis. Compared with cancers, women with benign disease had lower average: age, 52.5 versus 58.4 years (p<0.0001); serum CA125, 20 versus 239 U/mL (p<0.0001), neutrophil-to-lymphocyte ratio, 2.4 versus 3.5 (p<0.0001); and platelet-to-lymphocyte ratio, 158 versus 222 (p<0.0001); but greater average body mass index, 28.5 versus 26.8 kg/m2 (p=0.004), and lymphocyte-to-monocyte ratio, 5.6 versus 3.9 (p<0.0001). Correlations between counts and ratios and serum CA125 were seen in both epithelial ovarian cancer and benign disease groups and differed by menopausal status. In premenopausal women, a multivariate model including serum CA125, smoking, family history, lymphocytes, and monocytes performed similarly to the model with lymphocyte-to-monocyte ratio replacing counts. In postmenopausal women, a model including body mass index, parity, monocytes, and basophils performed similarly to the model replacing counts with platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio. Models including epidemiologic variables and either counts or ratios were better at fitting data than models with serum CA125 and menopausal status alone. A single model applying to all women overstated performance for premenopausal women and understated performance for postmenopausal women.ConclusionsEpidemiologic variables and differential counts or ratios better distinguished between benign and malignant disease when compared with serum CA125 alone using separate models for pre- and postmenopausal women. |
|---|---|
| AbstractList | Triaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables and preoperative differential blood counts to improve detection of ovarian cancer over CA125 alone.
From pathology reports, patients were classified as having: epithelial ovarian cancer (n=743), including fallopian tube and primary peritoneal cancer, non-epithelial ovarian cancers (n=46), non-ovarian cancers (n=122), or benign disease (1,129). From women with epithelial ovarian cancer, we excluded those who received prior neoadjuvant chemotherapy (n=19). Women were also excluded if they did not have a serum CA125 or complete blood count measured within 180 days prior to surgery (n=1099) or did not have both tests within 90 days of each other (n=13). Categorizing patients by menopausal status, we calculated Pearson correlations between differential counts or ratios and CA125, and used t tests to identity univariate predictors of malignancy and stepwise logistic regression and likelihood ratio tests to create models best distinguishing epithelial ovarian cancer from benign disease.
337 women with epithelial ovarian cancer and 365 with benign disease were included in the analysis. Compared with cancers, women with benign disease had lower average: age, 52.5 versus 58.4 years (p<0.0001); serum CA125, 20 versus 239 U/mL (p<0.0001), neutrophil-to-lymphocyte ratio, 2.4 versus 3.5 (p<0.0001); and platelet-to-lymphocyte ratio, 158 versus 222 (p<0.0001); but greater average body mass index, 28.5 versus 26.8 kg/m2 (p=0.004), and lymphocyte-to-monocyte ratio, 5.6 versus 3.9 (p<0.0001). Correlations between counts and ratios and serum CA125 were seen in both epithelial ovarian cancer and benign disease groups and differed by menopausal status. In premenopausal women, a multivariate model including serum CA125, smoking, family history, lymphocytes, and monocytes performed similarly to the model with lymphocyte-to-monocyte ratio replacing counts. In postmenopausal women, a model including body mass index, parity, monocytes, and basophils performed similarly to the model replacing counts with platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio. Models including epidemiologic variables and either counts or ratios were better at fitting data than models with serum CA125 and menopausal status alone. A single model applying to all women overstated performance for premenopausal women and understated performance for postmenopausal women.
Epidemiologic variables and differential counts or ratios better distinguished between benign and malignant disease when compared with serum CA125 alone using separate models for pre- and postmenopausal women. ObjectiveTriaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables and preoperative differential blood counts to improve detection of ovarian cancer over CA125 alone.MethodsFrom pathology reports, patients were classified as having: epithelial ovarian cancer (n=743), including fallopian tube and primary peritoneal cancer, non-epithelial ovarian cancers (n=46), non-ovarian cancers (n=122), or benign disease (1,129). From women with epithelial ovarian cancer, we excluded those who received prior neoadjuvant chemotherapy (n=19). Women were also excluded if they did not have a serum CA125 or complete blood count measured within 180 days prior to surgery (n=1099) or did not have both tests within 90 days of each other (n=13). Categorizing patients by menopausal status, we calculated Pearson correlations between differential counts or ratios and CA125, and used t tests to identity univariate predictors of malignancy and stepwise logistic regression and likelihood ratio tests to create models best distinguishing epithelial ovarian cancer from benign disease.Results337 women with epithelial ovarian cancer and 365 with benign disease were included in the analysis. Compared with cancers, women with benign disease had lower average: age, 52.5 versus 58.4 years (p<0.0001); serum CA125, 20 versus 239 U/mL (p<0.0001), neutrophil-to-lymphocyte ratio, 2.4 versus 3.5 (p<0.0001); and platelet-to-lymphocyte ratio, 158 versus 222 (p<0.0001); but greater average body mass index, 28.5 versus 26.8 kg/m2 (p=0.004), and lymphocyte-to-monocyte ratio, 5.6 versus 3.9 (p<0.0001). Correlations between counts and ratios and serum CA125 were seen in both epithelial ovarian cancer and benign disease groups and differed by menopausal status. In premenopausal women, a multivariate model including serum CA125, smoking, family history, lymphocytes, and monocytes performed similarly to the model with lymphocyte-to-monocyte ratio replacing counts. In postmenopausal women, a model including body mass index, parity, monocytes, and basophils performed similarly to the model replacing counts with platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio. Models including epidemiologic variables and either counts or ratios were better at fitting data than models with serum CA125 and menopausal status alone. A single model applying to all women overstated performance for premenopausal women and understated performance for postmenopausal women.ConclusionsEpidemiologic variables and differential counts or ratios better distinguished between benign and malignant disease when compared with serum CA125 alone using separate models for pre- and postmenopausal women. Triaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables and preoperative differential blood counts to improve detection of ovarian cancer over CA125 alone. From pathology reports, patients were classified as having: epithelial ovarian cancer (n=743), including fallopian tube and primary peritoneal cancer, non-epithelial ovarian cancers (n=46), non-ovarian cancers (n=122), or benign disease (1,129). From women with epithelial ovarian cancer, we excluded those who received prior neoadjuvant chemotherapy (n=19). Women were also excluded if they did not have a serum CA125 or complete blood count measured within 180 days prior to surgery (n=1099) or did not have both tests within 90 days of each other (n=13). Categorizing patients by menopausal status, we calculated Pearson correlations between differential counts or ratios and CA125, and used t tests to identity univariate predictors of malignancy and stepwise logistic regression and likelihood ratio tests to create models best distinguishing epithelial ovarian cancer from benign disease. 337 women with epithelial ovarian cancer and 365 with benign disease were included in the analysis. Compared with cancers, women with benign disease had lower average: age, 52.5 versus 58.4 years (p<0.0001); serum CA125, 20 versus 239 U/mL (p<0.0001), neutrophil-to-lymphocyte ratio, 2.4 versus 3.5 (p<0.0001); and platelet-to-lymphocyte ratio, 158 versus 222 (p<0.0001); but greater average body mass index, 28.5 versus 26.8 kg/m (p=0.004), and lymphocyte-to-monocyte ratio, 5.6 versus 3.9 (p<0.0001). Correlations between counts and ratios and serum CA125 were seen in both epithelial ovarian cancer and benign disease groups and differed by menopausal status. In premenopausal women, a multivariate model including serum CA125, smoking, family history, lymphocytes, and monocytes performed similarly to the model with lymphocyte-to-monocyte ratio replacing counts. In postmenopausal women, a model including body mass index, parity, monocytes, and basophils performed similarly to the model replacing counts with platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio. Models including epidemiologic variables and either counts or ratios were better at fitting data than models with serum CA125 and menopausal status alone. A single model applying to all women overstated performance for premenopausal women and understated performance for postmenopausal women. Epidemiologic variables and differential counts or ratios better distinguished between benign and malignant disease when compared with serum CA125 alone using separate models for pre- and postmenopausal women. Triaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables and preoperative differential blood counts to improve detection of ovarian cancer over CA125 alone.OBJECTIVETriaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables and preoperative differential blood counts to improve detection of ovarian cancer over CA125 alone.From pathology reports, patients were classified as having: epithelial ovarian cancer (n=743), including fallopian tube and primary peritoneal cancer, non-epithelial ovarian cancers (n=46), non-ovarian cancers (n=122), or benign disease (1,129). From women with epithelial ovarian cancer, we excluded those who received prior neoadjuvant chemotherapy (n=19). Women were also excluded if they did not have a serum CA125 or complete blood count measured within 180 days prior to surgery (n=1099) or did not have both tests within 90 days of each other (n=13). Categorizing patients by menopausal status, we calculated Pearson correlations between differential counts or ratios and CA125, and used t tests to identity univariate predictors of malignancy and stepwise logistic regression and likelihood ratio tests to create models best distinguishing epithelial ovarian cancer from benign disease.METHODSFrom pathology reports, patients were classified as having: epithelial ovarian cancer (n=743), including fallopian tube and primary peritoneal cancer, non-epithelial ovarian cancers (n=46), non-ovarian cancers (n=122), or benign disease (1,129). From women with epithelial ovarian cancer, we excluded those who received prior neoadjuvant chemotherapy (n=19). Women were also excluded if they did not have a serum CA125 or complete blood count measured within 180 days prior to surgery (n=1099) or did not have both tests within 90 days of each other (n=13). Categorizing patients by menopausal status, we calculated Pearson correlations between differential counts or ratios and CA125, and used t tests to identity univariate predictors of malignancy and stepwise logistic regression and likelihood ratio tests to create models best distinguishing epithelial ovarian cancer from benign disease.337 women with epithelial ovarian cancer and 365 with benign disease were included in the analysis. Compared with cancers, women with benign disease had lower average: age, 52.5 versus 58.4 years (p<0.0001); serum CA125, 20 versus 239 U/mL (p<0.0001), neutrophil-to-lymphocyte ratio, 2.4 versus 3.5 (p<0.0001); and platelet-to-lymphocyte ratio, 158 versus 222 (p<0.0001); but greater average body mass index, 28.5 versus 26.8 kg/m2 (p=0.004), and lymphocyte-to-monocyte ratio, 5.6 versus 3.9 (p<0.0001). Correlations between counts and ratios and serum CA125 were seen in both epithelial ovarian cancer and benign disease groups and differed by menopausal status. In premenopausal women, a multivariate model including serum CA125, smoking, family history, lymphocytes, and monocytes performed similarly to the model with lymphocyte-to-monocyte ratio replacing counts. In postmenopausal women, a model including body mass index, parity, monocytes, and basophils performed similarly to the model replacing counts with platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio. Models including epidemiologic variables and either counts or ratios were better at fitting data than models with serum CA125 and menopausal status alone. A single model applying to all women overstated performance for premenopausal women and understated performance for postmenopausal women.RESULTS337 women with epithelial ovarian cancer and 365 with benign disease were included in the analysis. Compared with cancers, women with benign disease had lower average: age, 52.5 versus 58.4 years (p<0.0001); serum CA125, 20 versus 239 U/mL (p<0.0001), neutrophil-to-lymphocyte ratio, 2.4 versus 3.5 (p<0.0001); and platelet-to-lymphocyte ratio, 158 versus 222 (p<0.0001); but greater average body mass index, 28.5 versus 26.8 kg/m2 (p=0.004), and lymphocyte-to-monocyte ratio, 5.6 versus 3.9 (p<0.0001). Correlations between counts and ratios and serum CA125 were seen in both epithelial ovarian cancer and benign disease groups and differed by menopausal status. In premenopausal women, a multivariate model including serum CA125, smoking, family history, lymphocytes, and monocytes performed similarly to the model with lymphocyte-to-monocyte ratio replacing counts. In postmenopausal women, a model including body mass index, parity, monocytes, and basophils performed similarly to the model replacing counts with platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio. Models including epidemiologic variables and either counts or ratios were better at fitting data than models with serum CA125 and menopausal status alone. A single model applying to all women overstated performance for premenopausal women and understated performance for postmenopausal women.Epidemiologic variables and differential counts or ratios better distinguished between benign and malignant disease when compared with serum CA125 alone using separate models for pre- and postmenopausal women.CONCLUSIONSEpidemiologic variables and differential counts or ratios better distinguished between benign and malignant disease when compared with serum CA125 alone using separate models for pre- and postmenopausal women. Triaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables and preoperative differential blood counts to improve detection of ovarian cancer over CA125 alone. From pathology reports, patients were classified as havingepithelial ovarian cancer (n=743), including fallopian tube and primary peritoneal cancer, non-epithelial ovarian cancers (n=46), non-ovarian cancers (n=122), or benign disease (1,129). From women with epithelial ovarian cancer, we excluded those who received prior neoadjuvant chemotherapy (n=19). Women were also excluded if they did not have a serum CA125 or complete blood count measured within 180 days prior to surgery (n=1099) or did not have both tests within 90 days of each other (n=13). Categorizing patients by menopausal status, we calculated Pearson correlations between differential counts or ratios and CA125, and used t tests to identity univariate predictors of malignancy and stepwise logistic regression and likelihood ratio tests to create models best distinguishing epithelial ovarian cancer from benign disease. 337 women with epithelial ovarian cancer and 365 with benign disease were included in the analysis. Compared with cancers, women with benign disease had lower averageage, 52.5 versus 58.4 years (p<0.0001); serum CA125, 20 versus 239 U/mL (p<0.0001), neutrophil-to-lymphocyte ratio, 2.4 versus 3.5 (p<0.0001); and platelet-to-lymphocyte ratio, 158 versus 222 (p<0.0001); but greater average body mass index, 28.5 versus 26.8 kg/m2 (p=0.004), and lymphocyte-to-monocyte ratio, 5.6 versus 3.9 (p<0.0001). Correlations between counts and ratios and serum CA125 were seen in both epithelial ovarian cancer and benign disease groups and differed by menopausal status. In premenopausal women, a multivariate model including serum CA125, smoking, family history, lymphocytes, and monocytes performed similarly to the model with lymphocyte-to-monocyte ratio replacing counts. In postmenopausal women, a model including body mass index, parity, monocytes, and basophils performed similarly to the model replacing counts with platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio. Models including epidemiologic variables and either counts or ratios were better at fitting data than models with serum CA125 and menopausal status alone. A single model applying to all women overstated performance for premenopausal women and understated performance for postmenopausal women. Epidemiologic variables and differential counts or ratios better distinguished between benign and malignant disease when compared with serum CA125 alone using separate models for pre- and postmenopausal women. |
| Author | Vitonis, Allison F Matulonis, Ursula Benjamin IV, William J Cramer, Daniel W Berkowitz, Ross Goodman, Annekathryn |
| AuthorAffiliation | Ob/Gyn Epidemiology, Brigham and Women’s Hospital, Boston, Massachusetts, USA, University of Michigan, Ann Arbor, Michigan, USA, Gynecologic Oncology, Brigham and Women’s Hospital, Boston, Massachusetts, USA, Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA, Dana Farber Cancer Institute, Boston, Massachusetts, USA |
| AuthorAffiliation_xml | – name: Ob/Gyn Epidemiology, Brigham and Women’s Hospital, Boston, Massachusetts, USA, University of Michigan, Ann Arbor, Michigan, USA, Gynecologic Oncology, Brigham and Women’s Hospital, Boston, Massachusetts, USA, Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA, Dana Farber Cancer Institute, Boston, Massachusetts, USA – name: 2 University of Michigan, Ann Arbor, Michigan, USA – name: 5 Dana Farber Cancer Institute, Boston, Massachusetts, USA – name: 4 Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA – name: 3 Gynecologic Oncology, Brigham and Women’s Hospital, Boston, Massachusetts, USA – name: 1 Ob/Gyn Epidemiology, Brigham and Women’s Hospital, Boston, Massachusetts, USA |
| Author_xml | – sequence: 1 givenname: Daniel W orcidid: 0000-0002-8024-3066 surname: Cramer fullname: Cramer, Daniel W email: dcramer@bwh.harvard.edu organization: Ob/Gyn Epidemiology, Brigham and Women's Hospital, Boston, Massachusetts, USA – sequence: 2 givenname: William J surname: Benjamin IV fullname: Benjamin IV, William J email: dcramer@bwh.harvard.edu organization: University of Michigan, Ann Arbor, Michigan, USA – sequence: 3 givenname: Allison F surname: Vitonis fullname: Vitonis, Allison F email: dcramer@bwh.harvard.edu organization: Ob/Gyn Epidemiology, Brigham and Women's Hospital, Boston, Massachusetts, USA – sequence: 4 givenname: Ross surname: Berkowitz fullname: Berkowitz, Ross email: dcramer@bwh.harvard.edu organization: Gynecologic Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA – sequence: 5 givenname: Annekathryn surname: Goodman fullname: Goodman, Annekathryn email: dcramer@bwh.harvard.edu organization: Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA – sequence: 6 givenname: Ursula surname: Matulonis fullname: Matulonis, Ursula email: dcramer@bwh.harvard.edu organization: Dana Farber Cancer Institute, Boston, Massachusetts, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32487682$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkktv1DAUhSNURB-wZ4UisUFCAb8fLJBQoYBUiQ1I7CzHuZ7x4IkHO5mKf4-naRF0UVZJ5PMdn9xzT5ujMY3QNE8xeoUxFa_DZuU6grDuEMIY0QfNCeaEd5hRdVTfEVOd0vj7cXNaygYhpAnSj5pjSpiSQpGT5uJ98B4yjFOwse1jSkPr0jxOrS3tlINdQTulFNswtrC3cbZTSGObfLuDuA-u3dpSoDxuHnobCzy5eZ413y4-fD3_1F1--fj5_N1l1wtCaEexpl6qvncA3ktGQBHNMOVECwySKKGZJ4wOikiQTnHSe-V7rpkg3GFBz5q3i-9u7rcwuJo722h2OWxt_mWSDebfkzGszSrtjazWQvNq8OLGIKefM5TJbENxEKMdIc3FEIY0VpoLVKXP70g3ac5j_T1DuKaCSn5t-OzvRH-i3I64CsQicDmVksEbF6brKdaAIRqMzKFLc-jSHLo0S5cVRHfAW-97ELYgVylOkMuPOF9BNmuwcVpXUV0ALmXdGIIRr191bRA-YG8WDGp1-1CJ4gKMDoaQwU1mSOG-O18ucL_d_D_hb2a90OE |
| CitedBy_id | crossref_primary_10_12677_ACM_2023_13112432 crossref_primary_10_3390_biomedicines10112683 crossref_primary_10_1186_s13048_022_00957_7 crossref_primary_10_1186_s13048_023_01116_2 |
| Cites_doi | 10.1016/S0301-2115(96)02662-0 10.1001/jama.1985.03360140090031 10.1016/j.ygyno.2014.01.026 10.1016/j.ygyno.2008.05.006 10.1016/j.ygyno.2010.08.028 10.1016/j.ajog.2010.03.043 10.1016/j.ejogrb.2007.05.012 10.1007/s00011-017-1026-6 10.1002/(SICI)1097-0142(19990501)85:9%3C2068::AID-CNCR25%3E3.0.CO;2-8 10.3802/jgo.2012.23.4.265 10.7150/jca.23606 10.1111/j.1471-0528.1990.tb02448.x 10.1016/j.exger.2005.08.006 10.1007/s13277-015-3533-9 10.1007/s00262-008-0516-3 10.1186/s13048-017-0315-6 10.1097/AOG.0b013e31821b5118 10.1016/j.ajog.2016.03.003 10.1111/j.1532-5415.1986.tb04906.x 10.1158/1055-9965.EPI-18-1120 10.7314/APJCP.2014.15.22.9781 10.1200/JCO.2005.01.7632 10.1007/s12094-011-0687-9 10.1016/j.ygyno.2008.11.011 |
| ContentType | Journal Article |
| Copyright | IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. 2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. |
| Copyright_xml | – notice: IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. – notice: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1136/ijgc-2019-001103 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Eastern Edition MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1525-1438 |
| EndPage | 743 |
| ExternalDocumentID | PMC7869695 32487682 10_1136_ijgc_2019_001103 00009577-202105000-00013 S1048891X24023405 ijgc |
| Genre | Journal Article Observational Study Research Support, N.I.H., Extramural |
| GeographicLocations | United States--US Massachusetts |
| GeographicLocations_xml | – name: United States--US – name: Massachusetts |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R35 CA197605 |
| GroupedDBID | --- .3N .Z2 0R~ 1OC 29J 31~ 36B 4.4 53G 5GY 5VS 7X7 8-1 8FI 8FJ AAHLL AAKAS AARTV AAXUO ABBUW ABJNI ABUWG ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACWDW ACWRI ACXNZ ACXQS ADZCM AENEX AFBPY AFEBI AFKRA AFTRI AFZJQ AGINI AHEFC AIZYK AJAOE AJNYG AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BFHJK BQLVK CAG CCPQU CO8 COF CS3 CXRWF DC6 DCZOG E.X EBS EJD EX3 F5P FDB FL- FYUFA FZ0 HAJ HMCUK HZI HZ~ IHE IN~ KD2 L-C LH4 LW6 M41 O9- OCUKA OHYEH ORVUJ OUVQU OVD OXXIT P2P RMJ ROL S4S TEORI UDS UKHRP V2I W3M W99 WOW X3V X3W YUY 6I. AAFTH AALRI AWKKM AAYWO AAYXX ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP CITATION CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PQEST PQQKQ PQUKI PRINS 7X8 PHGZM 5PM |
| ID | FETCH-LOGICAL-b6223-3193f78bbceeff742e82941352961e728694f243d827e7c852bf8fb594625c163 |
| IEDL.DBID | 7X7 |
| ISSN | 1048-891X 1525-1438 |
| IngestDate | Thu Aug 21 14:12:23 EDT 2025 Sat Sep 27 22:44:27 EDT 2025 Mon Jun 30 12:11:42 EDT 2025 Mon Jul 21 06:04:11 EDT 2025 Wed Sep 10 05:56:49 EDT 2025 Thu Apr 24 23:05:20 EDT 2025 Fri May 16 03:49:09 EDT 2025 Sat Feb 01 16:07:30 EST 2025 Thu Apr 24 22:50:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | ovarian cysts ovarian cancer |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc-nd/4.0 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b6223-3193f78bbceeff742e82941352961e728694f243d827e7c852bf8fb594625c163 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Contributors DWC was responsible for data collection and writing; WJB was responsible for data analysis and writing; AFV was responsible for database construction, data analysis, and writing; RB was responsible for subject recruitment and writing; AKG was responsible for subject recruitment and writing; and UM was responsible for subject recruitment and writing. |
| ORCID | 0000-0002-8024-3066 |
| OpenAccessLink | https://dx.doi.org/10.1136/ijgc-2019-001103 |
| PMID | 32487682 |
| PQID | 2593637595 |
| PQPubID | 5161120 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7869695 proquest_miscellaneous_2409189560 proquest_journals_2593637595 pubmed_primary_32487682 crossref_citationtrail_10_1136_ijgc_2019_001103 crossref_primary_10_1136_ijgc_2019_001103 wolterskluwer_health_00009577-202105000-00013 elsevier_sciencedirect_doi_10_1136_ijgc_2019_001103 bmj_primary_10_1136_ijgc_2019_001103 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-May-01 |
| PublicationDateYYYYMMDD | 2021-05-01 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-May-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Kidlington |
| PublicationTitle | International journal of gynecological cancer |
| PublicationTitleAlternate | Int J Gynecol Cancer |
| PublicationYear | 2021 |
| Publisher | Elsevier Inc by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology – name: Elsevier Limited |
| References | Jeyarajah, Ind, Skates 1999; 85 Moore, Jabre-Raughley, Brown 2010; 203 Givens, Mitchell, Harraway-Smith 2009; 80 Cramer, Vitonis, Welch 2010; 119 Pauler, Menon, McIntosh 2001; 10 Zhang, Liu, Hu 2015; 36 Johnson, Kessel, Riley 2008; 110 Grimm, Neaton, Ludwig 1985; 254 Prodromidou, Andreakos, Kazakos 2017; 66 Westhoff, Gollub, Patel 1990; 76 Leng, Xue, Huang 2005; 40 Williams, Labidi-Galy, Terry 2014; 132 Ueland, Desimone, Seamon 2011; 117 Jacobs, Oram, Fairbanks 1990; 97 Zahorec 2001; 102 Coleman, Herzog, Chan 2016; 215 Vernooij, Heintz, Coebergh 2009; 112 Kokcu, Kurtoglu, Celik 2014; 15 den Ouden, Ubachs, Stoot 1997; 72 Raungkaewmanee, Tangjitgamol, Manusirivithaya 2012; 23 Eo, Kim, Park 2018; 9 Timmerman, Testa, Bourne 2005; 23 Asher, Lee, Innamaa 2011; 13 Cho, Hur, Kim 2009; 58 Fortner, Vitonis, Schock 2017; 10 Bender, Nagel, Adler 1986; 34 Sasamoto, Babic, Rosner 2019; 28 Bishara, Griffin, Cargill 2008; 138 Ueland, Desimone, Seamon (bb0030) 2011; 117 Cramer, Vitonis, Welch (bb0080) 2010; 119 Westhoff, Gollub, Patel (bb0075) 1990; 76 Williams, Labidi-Galy, Terry (bb0125) 2014; 132 Cho, Hur, Kim (bb0110) 2009; 58 Vernooij, Heintz, Coebergh (bb0010) 2009; 112 Timmerman, Testa, Bourne (bb0045) 2005; 23 den Ouden, Ubachs, Stoot (bb0145) 1997; 72 Grimm, Neaton, Ludwig (bb0085) 1985; 254 Bender, Nagel, Adler (bb0090) 1986; 34 Jeyarajah, Ind, Skates (bb0050) 1999; 85 Fortner, Vitonis, Schock (bb0065) 2017; 10 Eo, Kim, Park (bb0135) 2018; 9 Leng, Xue, Huang (bb0095) 2005; 40 Kokcu, Kurtoglu, Celik (bb0115) 2014; 15 Zhang, Liu, Hu (bb0130) 2015; 36 Coleman, Herzog, Chan (bb0020) 2016; 215 Raungkaewmanee, Tangjitgamol, Manusirivithaya (bb0120) 2012; 23 Jacobs, Oram, Fairbanks (bb0015) 1990; 97 Zahorec (bb0100) 2001; 102 Sasamoto, Babic, Rosner (bb0070) 2019; 28 Asher, Lee, Innamaa (bb0105) 2011; 13 Givens, Mitchell, Harraway-Smith (bb0035) 2009; 80 Prodromidou, Andreakos, Kazakos (bb0040) 2017; 66 Pauler, Menon, McIntosh (bb0055) 2001; 10 Johnson, Kessel, Riley (bb0060) 2008; 110 Moore, Jabre-Raughley, Brown (bb0025) 2010; 203 Bishara, Griffin, Cargill (bb0140) 2008; 138 Givens (10.1136/ijgc-2019-001103_bb0035) 2009; 80 Bender (10.1136/ijgc-2019-001103_bb0090) 1986; 34 Timmerman (10.1136/ijgc-2019-001103_bb0045) 2005; 23 Williams (10.1136/ijgc-2019-001103_bb0125) 2014; 132 Jacobs (10.1136/ijgc-2019-001103_bb0015) 1990; 97 Vernooij (10.1136/ijgc-2019-001103_bb0010) 2009; 112 Johnson (10.1136/ijgc-2019-001103_bb0060) 2008; 110 Zhang (10.1136/ijgc-2019-001103_bb0130) 2015; 36 Ueland (10.1136/ijgc-2019-001103_bb0030) 2011; 117 Pauler (10.1136/ijgc-2019-001103_bb0055) 2001; 10 Coleman (10.1136/ijgc-2019-001103_bb0020) 2016; 215 Jeyarajah (10.1136/ijgc-2019-001103_bb0050) 1999; 85 Prodromidou (10.1136/ijgc-2019-001103_bb0040) 2017; 66 Sasamoto (10.1136/ijgc-2019-001103_bb0070) 2019; 28 Cramer (10.1136/ijgc-2019-001103_bb0080) 2010; 119 Cho (10.1136/ijgc-2019-001103_bb0110) 2009; 58 Kokcu (10.1136/ijgc-2019-001103_bb0115) 2014; 15 den Ouden (10.1136/ijgc-2019-001103_bb0145) 1997; 72 Zahorec (10.1136/ijgc-2019-001103_bb0100) 2001; 102 Moore (10.1136/ijgc-2019-001103_bb0025) 2010; 203 Raungkaewmanee (10.1136/ijgc-2019-001103_bb0120) 2012; 23 Westhoff (10.1136/ijgc-2019-001103_bb0075) 1990; 76 Eo (10.1136/ijgc-2019-001103_bb0135) 2018; 9 Bishara (10.1136/ijgc-2019-001103_bb0140) 2008; 138 Fortner (10.1136/ijgc-2019-001103_bb0065) 2017; 10 Grimm (10.1136/ijgc-2019-001103_bb0085) 1985; 254 Asher (10.1136/ijgc-2019-001103_bb0105) 2011; 13 Leng (10.1136/ijgc-2019-001103_bb0095) 2005; 40 |
| References_xml | – volume: 72 start-page: 73 year: 1997 article-title: Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/S0301-2115(96)02662-0 – volume: 254 start-page: 1932 year: 1985 article-title: Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality publication-title: JAMA doi: 10.1001/jama.1985.03360140090031 – volume: 132 start-page: 542 year: 2014 article-title: Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2014.01.026 – volume: 110 start-page: 383 year: 2008 article-title: The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2008.05.006 – volume: 119 start-page: 462 year: 2010 article-title: Correlates of the preoperative level of CA125 at presentation of ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2010.08.028 – volume: 203 start-page: 228.e1 year: 2010 article-title: Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2010.03.043 – volume: 102 start-page: 5 year: 2001 article-title: Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill publication-title: Bratisl Lek Listy – volume: 138 start-page: 71 year: 2008 article-title: Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/j.ejogrb.2007.05.012 – volume: 80 start-page: 815 year: 2009 article-title: Diagnosis and management of adnexal masses publication-title: Am Fam Physician – volume: 66 start-page: 467 year: 2017 article-title: The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer publication-title: Inflamm Res doi: 10.1007/s00011-017-1026-6 – volume: 85 start-page: 2068 year: 1999 article-title: Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19990501)85:9%3C2068::AID-CNCR25%3E3.0.CO;2-8 – volume: 23 start-page: 265 year: 2012 article-title: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer publication-title: J Gynecol Oncol doi: 10.3802/jgo.2012.23.4.265 – volume: 9 start-page: 1165 year: 2018 article-title: Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses publication-title: J Cancer doi: 10.7150/jca.23606 – volume: 97 start-page: 922 year: 1990 article-title: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer publication-title: Br J Obstet Gynaecol doi: 10.1111/j.1471-0528.1990.tb02448.x – volume: 40 start-page: 982 year: 2005 article-title: Baseline total and specific differential white blood cell counts and 5-year all-cause mortality in community-dwelling older women publication-title: Exp Gerontol doi: 10.1016/j.exger.2005.08.006 – volume: 36 start-page: 8831 year: 2015 article-title: Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients publication-title: Tumour Biol doi: 10.1007/s13277-015-3533-9 – volume: 10 start-page: 489 year: 2001 article-title: Factors influencing serum CA125II levels in healthy postmenopausal women publication-title: Cancer Epidemiol Biomarkers Prev – volume: 58 start-page: 15 year: 2009 article-title: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0516-3 – volume: 10 year: 2017 article-title: Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort publication-title: J Ovarian Res doi: 10.1186/s13048-017-0315-6 – volume: 117 start-page: 1289 year: 2011 article-title: Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors publication-title: Obstet Gynecol doi: 10.1097/AOG.0b013e31821b5118 – volume: 215 start-page: 82.e1 year: 2016 article-title: Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2016.03.003 – volume: 34 start-page: 649 year: 1986 article-title: Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. The Baltimore longitudinal study of aging publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.1986.tb04906.x – volume: 28 start-page: 1076 year: 2019 article-title: Predicting circulating CA125 levels among healthy premenopausal women publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-18-1120 – volume: 15 start-page: 9781 year: 2014 article-title: May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? publication-title: Asian Pac J Cancer Prev doi: 10.7314/APJCP.2014.15.22.9781 – volume: 23 start-page: 8794 year: 2005 article-title: Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group publication-title: J Clin Oncol doi: 10.1200/JCO.2005.01.7632 – volume: 13 start-page: 499 year: 2011 article-title: Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer publication-title: Clin Transl Oncol doi: 10.1007/s12094-011-0687-9 – volume: 112 start-page: 455 year: 2009 article-title: Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2008.11.011 – volume: 76 start-page: 428 year: 1990 article-title: CA 125 levels in menopausal women publication-title: Obstet Gynecol – volume: 13 start-page: 499 year: 2011 end-page: 503 ident: bb0105 article-title: Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer publication-title: Clin Transl Oncol – volume: 110 start-page: 383 year: 2008 end-page: 9 ident: bb0060 article-title: The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial publication-title: Gynecol Oncol – volume: 215 start-page: 82.e1 year: 2016 end-page: 2 ident: bb0020 article-title: Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses publication-title: Am J Obstet Gynecol – volume: 117 start-page: 1289 year: 2011 end-page: 97 ident: bb0030 article-title: Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors publication-title: Obstet Gynecol – volume: 119 start-page: 462 year: 2010 end-page: 8 ident: bb0080 article-title: Correlates of the preoperative level of CA125 at presentation of ovarian cancer publication-title: Gynecol Oncol – volume: 132 start-page: 542 year: 2014 end-page: 50 ident: bb0125 article-title: Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer publication-title: Gynecol Oncol – volume: 23 start-page: 265 year: 2012 end-page: 73 ident: bb0120 article-title: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer publication-title: J Gynecol Oncol – volume: 72 start-page: 73 year: 1997 end-page: 7 ident: bb0145 article-title: Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours publication-title: Eur J Obstet Gynecol Reprod Biol – volume: 138 start-page: 71 year: 2008 end-page: 5 ident: bb0140 article-title: Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer publication-title: Eur J Obstet Gynecol Reprod Biol – volume: 76 start-page: 428 year: 1990 end-page: 31 ident: bb0075 article-title: CA 125 levels in menopausal women publication-title: Obstet Gynecol – volume: 9 start-page: 1165 year: 2018 end-page: 72 ident: bb0135 article-title: Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses publication-title: J Cancer – volume: 23 start-page: 8794 year: 2005 end-page: 801 ident: bb0045 article-title: Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group publication-title: J Clin Oncol – volume: 36 start-page: 8831 year: 2015 end-page: 7 ident: bb0130 article-title: Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients publication-title: Tumour Biol – volume: 10 year: 2017 ident: bb0065 article-title: Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort publication-title: J Ovarian Res – volume: 10 start-page: 489 year: 2001 end-page: 93 ident: bb0055 article-title: Factors influencing serum CA125II levels in healthy postmenopausal women publication-title: Cancer Epidemiol Biomarkers Prev – volume: 58 start-page: 15 year: 2009 end-page: 23 ident: bb0110 article-title: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment publication-title: Cancer Immunol Immunother – volume: 112 start-page: 455 year: 2009 end-page: 61 ident: bb0010 article-title: Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands publication-title: Gynecol Oncol – volume: 66 start-page: 467 year: 2017 end-page: 75 ident: bb0040 article-title: The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer publication-title: Inflamm Res – volume: 34 start-page: 649 year: 1986 end-page: 54 ident: bb0090 article-title: Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. The Baltimore longitudinal study of aging publication-title: J Am Geriatr Soc – volume: 28 start-page: 1076 year: 2019 end-page: 85 ident: bb0070 article-title: Predicting circulating CA125 levels among healthy premenopausal women publication-title: Cancer Epidemiol Biomarkers Prev – volume: 15 start-page: 9781 year: 2014 end-page: 4 ident: bb0115 article-title: May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? publication-title: Asian Pac J Cancer Prev – volume: 254 start-page: 1932 year: 1985 end-page: 7 ident: bb0085 article-title: Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality publication-title: JAMA – volume: 40 start-page: 982 year: 2005 end-page: 7 ident: bb0095 article-title: Baseline total and specific differential white blood cell counts and 5-year all-cause mortality in community-dwelling older women publication-title: Exp Gerontol – volume: 80 start-page: 815 year: 2009 end-page: 20 ident: bb0035 article-title: Diagnosis and management of adnexal masses publication-title: Am Fam Physician – volume: 102 start-page: 5 year: 2001 end-page: 14 ident: bb0100 article-title: Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill publication-title: Bratisl Lek Listy – volume: 97 start-page: 922 year: 1990 end-page: 9 ident: bb0015 article-title: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer publication-title: Br J Obstet Gynaecol – volume: 203 start-page: 228.e1 year: 2010 end-page: 6 ident: bb0025 article-title: Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass publication-title: Am J Obstet Gynecol – volume: 85 start-page: 2068 year: 1999 end-page: 72 ident: bb0050 article-title: Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women publication-title: Cancer – volume: 97 start-page: 922 year: 1990 ident: 10.1136/ijgc-2019-001103_bb0015 article-title: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer publication-title: Br J Obstet Gynaecol doi: 10.1111/j.1471-0528.1990.tb02448.x – volume: 34 start-page: 649 year: 1986 ident: 10.1136/ijgc-2019-001103_bb0090 article-title: Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. The Baltimore longitudinal study of aging publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.1986.tb04906.x – volume: 119 start-page: 462 year: 2010 ident: 10.1136/ijgc-2019-001103_bb0080 article-title: Correlates of the preoperative level of CA125 at presentation of ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2010.08.028 – volume: 72 start-page: 73 year: 1997 ident: 10.1136/ijgc-2019-001103_bb0145 article-title: Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/S0301-2115(96)02662-0 – volume: 10 year: 2017 ident: 10.1136/ijgc-2019-001103_bb0065 article-title: Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort publication-title: J Ovarian Res doi: 10.1186/s13048-017-0315-6 – volume: 40 start-page: 982 year: 2005 ident: 10.1136/ijgc-2019-001103_bb0095 article-title: Baseline total and specific differential white blood cell counts and 5-year all-cause mortality in community-dwelling older women publication-title: Exp Gerontol doi: 10.1016/j.exger.2005.08.006 – volume: 110 start-page: 383 year: 2008 ident: 10.1136/ijgc-2019-001103_bb0060 article-title: The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2008.05.006 – volume: 117 start-page: 1289 year: 2011 ident: 10.1136/ijgc-2019-001103_bb0030 article-title: Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors publication-title: Obstet Gynecol doi: 10.1097/AOG.0b013e31821b5118 – volume: 132 start-page: 542 year: 2014 ident: 10.1136/ijgc-2019-001103_bb0125 article-title: Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2014.01.026 – volume: 138 start-page: 71 year: 2008 ident: 10.1136/ijgc-2019-001103_bb0140 article-title: Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/j.ejogrb.2007.05.012 – volume: 76 start-page: 428 year: 1990 ident: 10.1136/ijgc-2019-001103_bb0075 article-title: CA 125 levels in menopausal women publication-title: Obstet Gynecol – volume: 15 start-page: 9781 year: 2014 ident: 10.1136/ijgc-2019-001103_bb0115 article-title: May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? publication-title: Asian Pac J Cancer Prev doi: 10.7314/APJCP.2014.15.22.9781 – volume: 58 start-page: 15 year: 2009 ident: 10.1136/ijgc-2019-001103_bb0110 article-title: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0516-3 – volume: 9 start-page: 1165 year: 2018 ident: 10.1136/ijgc-2019-001103_bb0135 article-title: Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses publication-title: J Cancer doi: 10.7150/jca.23606 – volume: 112 start-page: 455 year: 2009 ident: 10.1136/ijgc-2019-001103_bb0010 article-title: Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2008.11.011 – volume: 13 start-page: 499 year: 2011 ident: 10.1136/ijgc-2019-001103_bb0105 article-title: Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer publication-title: Clin Transl Oncol doi: 10.1007/s12094-011-0687-9 – volume: 80 start-page: 815 year: 2009 ident: 10.1136/ijgc-2019-001103_bb0035 article-title: Diagnosis and management of adnexal masses publication-title: Am Fam Physician – volume: 23 start-page: 265 year: 2012 ident: 10.1136/ijgc-2019-001103_bb0120 article-title: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer publication-title: J Gynecol Oncol doi: 10.3802/jgo.2012.23.4.265 – volume: 66 start-page: 467 year: 2017 ident: 10.1136/ijgc-2019-001103_bb0040 article-title: The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer publication-title: Inflamm Res doi: 10.1007/s00011-017-1026-6 – volume: 203 start-page: 228.e1 year: 2010 ident: 10.1136/ijgc-2019-001103_bb0025 article-title: Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2010.03.043 – volume: 85 start-page: 2068 year: 1999 ident: 10.1136/ijgc-2019-001103_bb0050 article-title: Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19990501)85:9%3C2068::AID-CNCR25%3E3.0.CO;2-8 – volume: 36 start-page: 8831 year: 2015 ident: 10.1136/ijgc-2019-001103_bb0130 article-title: Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients publication-title: Tumour Biol doi: 10.1007/s13277-015-3533-9 – volume: 23 start-page: 8794 year: 2005 ident: 10.1136/ijgc-2019-001103_bb0045 article-title: Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group publication-title: J Clin Oncol doi: 10.1200/JCO.2005.01.7632 – volume: 102 start-page: 5 year: 2001 ident: 10.1136/ijgc-2019-001103_bb0100 article-title: Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill publication-title: Bratisl Lek Listy – volume: 10 start-page: 489 year: 2001 ident: 10.1136/ijgc-2019-001103_bb0055 article-title: Factors influencing serum CA125II levels in healthy postmenopausal women publication-title: Cancer Epidemiol Biomarkers Prev – volume: 254 start-page: 1932 year: 1985 ident: 10.1136/ijgc-2019-001103_bb0085 article-title: Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality publication-title: JAMA doi: 10.1001/jama.1985.03360140090031 – volume: 215 start-page: 82.e1 year: 2016 ident: 10.1136/ijgc-2019-001103_bb0020 article-title: Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2016.03.003 – volume: 28 start-page: 1076 year: 2019 ident: 10.1136/ijgc-2019-001103_bb0070 article-title: Predicting circulating CA125 levels among healthy premenopausal women publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-18-1120 |
| SSID | ssj0009209 |
| Score | 2.3252926 |
| Snippet | ObjectiveTriaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in... Triaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary... |
| SourceID | pubmedcentral proquest pubmed crossref wolterskluwer elsevier bmj |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 733 |
| SubjectTerms | Aged Biomarkers Breast cancer CA-125 Antigen - blood Carcinoma, Ovarian Epithelial - blood Carcinoma, Ovarian Epithelial - diagnosis Carcinoma, Ovarian Epithelial - pathology Chemotherapy Diagnosis, Differential Female Gastric cancer Humans Membrane Proteins - blood Middle Aged Ovarian cancer ovarian cysts Ovarian Neoplasms - blood Ovarian Neoplasms - diagnosis Ovarian Neoplasms - pathology Pelvic Neoplasms - diagnosis Prospective Studies Womens health |
| Title | Differential blood count as triage tool in evaluation of pelvic masses |
| URI | https://ijgc.bmj.com/content/31/5/733.full https://dx.doi.org/10.1136/ijgc-2019-001103 https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00009577-202105000-00013 https://www.ncbi.nlm.nih.gov/pubmed/32487682 https://www.proquest.com/docview/2593637595 https://www.proquest.com/docview/2409189560 https://pubmed.ncbi.nlm.nih.gov/PMC7869695 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fa9swEBZbC2Mwyn4vXVc06MseRGpZtqSn0m0NZdAyxgp5E5IstelSO21S9u_vzpaThbLs2VZin0667_Od7iPkwOpDkWWWMyG8Y0KJwFxRWRYy7aw_rGzUeMD57Lw8vRDfxsU4fXCbp7LKfk9sN-qq8fiNfMhRei6XhS6OZrcMVaMwu5okNB6T7QyQCEo3yLFcNd3tSjyAcSimdDbu05R5OZxcX3rwEDzBgxEQmwa6m-t_BaeH4PNhDeWz3w3mt-e_2vL2v4LU6DnZSeiSHnfu8II8CvVL8uQs5c9fkdHXpIcC63pK26J12qpFUDunKOBxGeiiaaZ0UtNVH3DaRDoLU9hT6I3FJPFrcjE6-fnllCUlBeZKiP-w0eo8SuUchMQYgQ0HxTWEL0y6ZkFyVWoRucgrxWWQXhXcRRVdoQXQIw-Q7Q3Zqps6vCNU86iCiL7iFRceCK70QLpkyKyonLJ8QA7AkGbW9cowLcfIS4P2Nmhv09l7QIa9pY1P3chRFGO6YcSn5Yj__3reT55JSKJDCAYCxYZRe_08m7SS52bldwPycXkZ1iAmVmwdmnu4B0hyppBpDsjbzi2WjwiAFQKOArvINYdZ3oD9vdev1JOrts-3hGkp8X_ZmmuZ7oSsaeF9ISW4MfD2IrUIyPLdza_xnjzFAV3R5h7ZWtzdhw8ArBZuv109-2T788n59x9_AJrFHl0 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwESmvimbICRxgMPURfHiZ2HCQFb1bG1QmiT-mbsxB4dXVJop4l_bn_b7hKnpZooT3tOnI_z5e5-ubvfEbKt0x0ehpoFnGcm4JLbwMS5DmyYGp3t5Nql2ODcHyS9E_5lGA_XyFXTC4NllY1NrAx1Xmb4j7zDcPRcJOI0_jD5FeDUKMyuNiM0tB-tkO9WFGO-sePQ_rkECDfdPdiD_X7HWHf_-HMv8FMGApOAbwQjlEZOSGPAXTgHSNFKloJpx4RkaAWTScod41EumbAikzEzTjoTpxygQwbhDFz3Dlnn-AOlRdY_7Q--flvQ_tZFJoB5ZCDTcNgkSqOkMzo7zUBHsYcIfTDSFprzs3-5x5vh780qzgeXJWbYpz-rAvu_3GT3Idnw8S39WCvkI7Jmi8fkbt9n8J-Q7p6fyAKWZUyrsnlaCZXqKcURIqeWzspyTEcFXTCR09LRiR2DVaPnGtPUT8nJrUj5GWkVZWFfEJoyJy13Wc5yxjOA2CID2CdsqHlupGZtsg2CVJOarUNVKCdKFMpbobxVLe826TSSVpnnQ8exHOMVK97PV_z_6lGzecrHMnWMosBVrVi11eyz8rZkqhaa3yZv54fBCmBqRxe2vIBzAKaHErFumzyv1WL-iBAyg8uTIBexpDDzE5BhfPlIMfpRMY0L2JYE7xssqZaqe3RVBTBiIUCNGcTpnqQgjF6ufo035F7vuH-kjg4Gh5vkPi6uS0i3SGv2-8K-gjBvZl77b4mS77f9-V4DsgFd9w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELbGJk1ICPFzFAYYaTzwEHVxnNh5mBDQVRtj1YSY1DdjO_bo6JJCO038i_xV3CVOSzVRnvacOE3O57v7enffEbKj810ex5pFnFsTccldZNJCRy7Ojba7hfY5NjgfD7KDU_5xmA7XyO-2FwbLKlubWBvqorL4H3mX4ei5RKR52vWhLOKk1387-RHhBCnMtLbjNHQYs1Ds1XRjocnjyP26Ajg33Tvswd6_Zqy__-XDQRQmDkQmAz8JBilPvJDGgOvwHlCjkywHM4_JydgJJrOce8aTQjLhhJUpM156k-YcYISF0Aaee4tsCPD6AAQ33u8PTj4vKICbghPAPzKSeTxsk6ZJ1h2dn1nQV-wnQn-MFIbm4vxfrvJ6KHy9ovPOVYXZ9un3utj-L5fZv0fuhliXvmuU8z5Zc-UDsnkcsvkPSb8XprOAlRnTuoSe1kKlekpxnMiZo7OqGtNRSRes5LTydOLGYOHohcaU9SNyeiNSfkzWy6p0TwjNmZeOe1uwgnELcFtYgIDCxZoXRmrWITsgSDVpmDtUjXiSTKG8FcpbNfLukG4raWUDNzqO6BivWPFmvuL_T0_azVMhrmniFQVua8Wq7XafVbArU7U4BR3yan4ZLAKmeXTpqku4ByB7LBH3dshWoxbzV4TwGdyfBLmIJYWZ34Bs48tXytG3mnVcwLZk-LvRkmqppl9X1WAjFQLUmEHMHggL4uTp6s94STbhGKtPh4OjZ-Q2rm2qSbfJ-uznpXsOEd_MvAhHiZKvN316_wCnrWI7 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+blood+count+as+triage+tool+in+evaluation+of+pelvic+masses&rft.jtitle=International+journal+of+gynecological+cancer&rft.au=Cramer%2C+Daniel+W&rft.au=Benjamin%2C+William+J&rft.au=Vitonis%2C+Allison+F&rft.au=Berkowitz%2C+Ross&rft.date=2021-05-01&rft.pub=by+the+International+Gynecologic+Cancer+Society+and+the+European+Society+of+Gynaecological+Oncology&rft.issn=1048-891X&rft.volume=31&rft.issue=5&rft.spage=733&rft.epage=743&rft_id=info:doi/10.1136%2Fijgc-2019-001103&rft.externalDocID=00009577-202105000-00013 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1048-891X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1048-891X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1048-891X&client=summon |